Researchers at Tarbiat Modares University in Tehran, Iran, reported that they have produced a highly sensitive radionuclide imaging technology which could be effective in diagnosing early stage breast cancer.
The new radionuclide has shown promising results in both imaging and diagnosing affected tissue with radio-immunoscintigraphy—a new technique for detecting cancerous cells in nuclear medicine, according to the researchers.
They reported that PR81 is an antibody recognized by a mouse monoclonal antibody raised against human breast adenocarcinoma; high concentrations of the marked antibody are reported in the tumoral tissue of the affected BALB/c mice.
Findings revealed that the high concentration of the marked antibody, four to 36 hours after the injection of the radionuclide, can detect breast cancer with high sensitivity.
The Tarbiat researchers concluded that compared to the available diagnostic methods (mammography and biopsy), the new technique can more accurately detect breast cancer in its early stages, adding that the method is particularly helpful in patients with suspected breast cancer.